SFA Therapeutics GTM brain

SFA Therapeutics develops investigational oral immune-modulating drug candidates for psoriasis and other inflammation-linked diseases.

category

Clinical-stage immunology therapeutics

market profile

  • text: SFA-002 is an investigational oral psoriasis candidate with an open-label 28-person Phase 1b study; the company says Phase 2 is in preparation.
  • text: Potential future competition includes established oral psoriasis medicines such as Otezla and Sotyktu, as well as biologics.

personas

  • title: Biopharma immunology licensing executive
    pains:
    • Finding differentiated assets with credible human data and defensible IP
    • Weighing trial, regulatory and funding risks before committing to a partnership
  • title: Dermatology clinical investigator
    pains:
    • Patients need more convenient systemic options
    • An open-label signal needs validation against placebo and an established oral comparator
  • title: Life sciences investor
    pains:
    • Funding a controlled trial before commercial revenue
    • Assessing whether a platform can produce multiple viable clinical programs

icp

  • text: Potential development partners are biopharma companies with immunology or dermatology portfolios and clinical development capacity; size is not specified.
  • text: Dermatology research sites able to conduct controlled plaque psoriasis studies are relevant trial collaborators, particularly US sites.

message pillars

  • text: Position the lead candidate around convenient oral administration.
  • text: Explain the differentiated proposed gut-immune mechanism.
  • text: Present Phase 1b safety as preliminary evidence, with the open-label limitation.

objections

  • objection: Is SFA-002 approved and proven effective?
    response: No. It is investigational, and the early open-label findings require controlled confirmation.
  • objection: How does it compare with established oral therapy?
    response: A registered study proposes a comparison with apremilast and placebo; outcomes are not established by that registration.

competitors

  • name: Amgen
    why: Otezla is an established oral psoriasis drug and a comparator in the registered SFA study.
  • name: Bristol Myers Squibb
    why: Sotyktu is another oral psoriasis therapy competing for systemic treatment.
  • name: Johnson & Johnson
    why: Its oral Icotyde and injectable psoriasis portfolio compete in the same treatment market.

influencers

  • name: Ira Spector
    url: https://www.linkedin.com/in/ira-spector-00414310
    why: Co-founder and scientific leader who posts about the development program.

keywords

  • oral psoriasis clinical trial
  • plaque psoriasis drug development
  • gut immune axis therapeutics
  • short chain fatty acid drug
  • immunology licensing
  • psoriasis phase 2

voice

  • Clinical and mechanism-oriented
  • Evidence-led with investigational cautions
  • Optimistic about immune reset

signals

  • text: A pharma company is seeking clinical-stage dermatology licensing opportunities.
  • text: A research site is expanding psoriasis trial capacity or enrolling for systemic therapy studies.

pricing

model: unknown

motion

unknown

channels

  • LinkedIn
  • industry conferences
  • press releases

confidence

medium

Founders

  • name: Ira Spector
    title: Founder
    role: Founder
    bio: Dr. Spector is the co-founder of SFA, a microbiome-derived pharmaceutical company focused on new advancements in the treatment inflammatory diseases. An experienced drug developer with over 30 years of experience, he helped develop 34 drugs and 12 medical devices, including Enbrel, Effexor, Protonix, Prevenar, Ozurdex, Botox for Overactive Bladder, Chronic Migraine and Cerebral Palsy. He holds BS degrees in Physics and EE from Washington University, an MBA from Drexel, and a PhD from Rutgers.
  • name: Alla Arzumanyan
    title: Founder
    role: Founder
    bio: MS is Microbiology, PhD in Biotechnology, Assistant Professor at Temple University, Co-Founder and Co-Inventor at SFA Therapeutics, Inc. Performed a case-control, Proof-of-Activity Human study to evaluate treatment effect of SFA002 drug (proprietary of SFA Therapeutics, Inc.) on patients with plaque psoriasis. Worked with Axella Research on pre-IND application for SFA002. Worked with HEC (Sunshine Lake Pharma Co., China), Theravectys, and ThirdLaw LLC (still collaborating with the latter)
  • name: Mark Feitelson
    title: Founder
    role: Founder
    bio: Mark Feitelson received his Ph.D. in Microbiology/Immunology from UCLA. He began his work with hepatitis B at Stanford University, and was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (Nobel laureate). In 1991, Dr. Feitelson moved to Thomas Jefferson University, and in 2007, to Temple University as a Professor of Biology. His work has been supported by NIH, industry and foundations. He has more than 150 publications and 180 abstracts. He is also CSO of SFA Therapeutics.

Back to YC companies